LeMaitre Vascular, Inc.
LMATLeMaitre Vascular, Inc. is a medical device company specializing in the development, manufacture, and commercialization of surgical solutions for peripheral vascular and cardiac use. Established to address the needs of vascular surgeons, the company offers a broad portfolio of products including vascular grafts, angioplasty balloons, stents, and other devices used in minimally invasive surgical procedures. LeMaitre Vascular serves a global customer base with an emphasis on improving patient outcomes through innovative technology.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 4, 2025 | $0.20 | 2025-11-20 | 2025-11-20 |
| September 4, 2025 | $0.20 | 2025-08-21 | 2025-08-21 |
| May 29, 2025 | $0.20 | 2025-05-15 | 2025-05-15 |
| March 27, 2025 | $0.20 | 2025-03-13 | 2025-03-13 |
| December 5, 2024 | $0.16 | 2024-11-21 | 2024-11-21 |
Dividends Summary
- Consistent Payer: LeMaitre Vascular, Inc. has rewarded shareholders with 60 dividend payments over the past 14 years.
- Total Returned Value: Investors who held LMAT shares during this period received a total of $4.94 per share in dividend income.
- Latest Payout: The most recent dividend of $0.20/share was paid 50 days ago, on December 4, 2025.
- Yield & Schedule: LMAT currently pays dividends quarterly with an annual yield of 0.95%.
- Dividend Growth: Since 2011, the dividend payout has grown by 900.0%, from $0.02 to $0.20.
- Dividend Reliability: LMAT has maintained or increased its dividend for 60 consecutive payments.
Company News
LeMaitre Vascular will release its third quarter 2025 financial results on November 6, 2025, after market close, with a conference call scheduled for 5:00 PM EST to discuss results and company outlook.
LeMaitre Vascular reported strong Q2 2025 financial results, with GAAP revenue of $64.2 million, exceeding estimates and growing 15% year-over-year. The company saw significant growth in catheters and grafts, expanded gross margins to 70%, and raised full-year guidance.
Anteris Technologies Global Corp. announced the appointments of David Roberts and Gregory Moss to its Board of Directors, as the company transitions to its next phase of growth with the upcoming global pivotal PARADIGM study for its DurAVR® Transcatheter Heart Valve.
LeMaitre Vascular, Inc. announced its intention to offer $150 million aggregate principal amount of Convertible Senior Notes due 2030 in a private offering. The company plans to use the net proceeds for working capital and general purposes, including potential acquisitions.
LeMaitre Vascular, a provider of devices for peripheral vascular disease, announced that its President, David Roberts, will present at three upcoming investor conferences in November 2024.
